Q2 2025 EPS Estimates for McKesson Co. Raised by Leerink Partnrs (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Investment analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for shares of McKesson in a research report issued to clients and investors on Monday, April 22nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $7.45 per share for the quarter, up from their prior forecast of $7.36. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for McKesson’s current full-year earnings is $27.59 per share. Leerink Partnrs also issued estimates for McKesson’s FY2025 earnings at $31.37 EPS.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping analysts’ consensus estimates of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The business had revenue of $80.90 billion for the quarter, compared to analysts’ expectations of $77.93 billion. During the same period in the prior year, the company posted $6.90 EPS. The business’s revenue for the quarter was up 14.8% on a year-over-year basis.

A number of other equities research analysts have also recently commented on MCK. Citigroup increased their price objective on shares of McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Argus raised their price target on shares of McKesson from $510.00 to $570.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Barclays assumed coverage on shares of McKesson in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 price target on the stock. Morgan Stanley raised their price target on shares of McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a research note on Monday, April 15th. Finally, SVB Leerink assumed coverage on shares of McKesson in a research note on Monday, February 26th. They set an “outperform” rating and a $600.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, McKesson presently has an average rating of “Moderate Buy” and an average price target of $533.50.

McKesson Trading Up 0.9 %

Shares of NYSE MCK opened at $531.87 on Tuesday. The stock has a market cap of $69.89 billion, a price-to-earnings ratio of 24.10, a PEG ratio of 1.42 and a beta of 0.45. McKesson has a 52 week low of $352.34 and a 52 week high of $543.00. The company’s 50-day moving average price is $526.12 and its 200 day moving average price is $488.15.

Institutional Trading of McKesson

Several large investors have recently bought and sold shares of MCK. Douglass Winthrop Advisors LLC grew its position in shares of McKesson by 1.4% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 1,512 shares of the company’s stock worth $700,000 after buying an additional 21 shares in the last quarter. Addison Advisors LLC grew its position in shares of McKesson by 7.9% during the fourth quarter. Addison Advisors LLC now owns 299 shares of the company’s stock worth $138,000 after buying an additional 22 shares in the last quarter. Evergreen Wealth Solutions LLC grew its position in shares of McKesson by 1.2% during the fourth quarter. Evergreen Wealth Solutions LLC now owns 1,931 shares of the company’s stock worth $894,000 after buying an additional 22 shares in the last quarter. RMR Wealth Builders boosted its holdings in McKesson by 5.2% in the first quarter. RMR Wealth Builders now owns 464 shares of the company’s stock worth $249,000 after purchasing an additional 23 shares during the period. Finally, Keystone Financial Services boosted its holdings in McKesson by 2.1% in the fourth quarter. Keystone Financial Services now owns 1,192 shares of the company’s stock worth $552,000 after purchasing an additional 24 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 3,473 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the transaction, the chief executive officer now owns 43,445 shares in the company, valued at $22,789,074.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other McKesson news, EVP Leann B. Smith sold 186 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the sale, the executive vice president now owns 1,511 shares of the company’s stock, valued at $749,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 3,473 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the sale, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were issued a dividend of $0.62 per share. The ex-dividend date was Thursday, February 29th. This represents a $2.48 annualized dividend and a dividend yield of 0.47%. McKesson’s payout ratio is currently 11.24%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.